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Abstract To evaluate the efficacy of palivizumab in infants
of 29 to 32 weeks of gestational age (GA) based on a risk
score tool developed for Austria. Retrospective single-center
cohort study including all preterm infants of 29 (+0) to 32 (+6)
weeks of GA born between 2004 and 2012 at a tertiary care
university hospital. Data on RSV-related hospitalizations over
the first 2 years of life were analyzed and compared between
those having received palivizumab and those without. The
study population was comprised of 789 of 816 screened in-
fants, of whom 262 (33%) had received palivizumab and 527
(67%) had not. Nine of 107 rehospitalizations (8.4%) in the
palivizumab group compared to 32 of 156 rehospitalizations
(20.5%) in the group without prophylaxis were tested RSV-
positive (p = 0.004; OR 0.356 [CI 90% 0.184–0.689]). Proven
and calculated RSV hospitalization rate was 3.1% (8/262) in
the palivizumab group and 5.9% (31/527) in the group with-
out (p = 0.042; OR 0.504 [CI 90% 0.259–0.981]). Increasing
number of risk factors (up to three) increased the RSV hospi-
talization rate in infants with (6.1%) and without (9.0%) pro-
phylaxis. RSV-associated hospitalizations did not differ be-
tween groups with regard to length of stay, severity of infec-
tion, age at hospitalization, demand of supplemental oxygen,
need for mechanical ventilation, and admission rate to the
ICU. A risk score tool developed for infants of 29 to 32 weeks
of gestational age led to a reduction of RSV-associated hospi-
talizations without influencing the severity of disease.
Introduction
Respiratory syncytial virus (RSV)-related hospitalization rates
have been reported to range from 2 to 18% for preterm infants
of equal or less than 32 weeks of gestational age (GA) without
bronchopulmonary dysplasia (BPD), and from 7.6 to 59% for
those having diagnosis of BPD [1]. Our own data from an
observational multicenter nation-wide study of preterm in-
fants of 29 to 32 weeks of GA revealed a hospitalization rate
of 4.5% (36/801), with differences between the two included
RSV seasons of 3.9% compared to 7.8% (p = 0.042) [2]. This
relatively low RSV hospitalization rate on the one hand and a
nation-wide heterogeneity of RSV prophylaxis reimburse-
ment by the insurance companies in Austria on the other hand
led to a revision of the initial Austrian guidelines for
palivizumab prophylaxis [3] that had adopted until then the
AAP guidelines [4]. Additionally, a RSV risk score tool was
developed by an experts’ round to tailor palivizumab prophy-
laxis to the infants at highest risk for RSV-related hospitaliza-
tion in this age group [5]. Risk factors included in the model
were based on literature findings with regard to RSV risk
factors summarized elsewhere [6, 7]. Definitively, the experts’
round [5] discussed on the basis of the risk factors found by
the Austrian RSV 29-32 Study Group [2] and their own data
[8].The discussion was further influenced by the findings of
the PICNIC [9] and IRIS study [10] in preterm infants of 33 to
35 weeks gestational. Some unresolved issues in the discus-
sion of different findings in both studies [11] were simplified
by the committee. Thus, briefly, a birth weight below 1,500
grams, presence of neurological disease, discharge between
October 1 and March 31, siblings of preschool and school
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age, multiple birth, day-care attendance, low socioeconomic
status/crowding, and passive tobacco smoke exposure were
included in the model (see Table 1). Four points or more
qualified an infant for palivizumab prophylaxis. Presence of
BPD, hemodynamically significant congenital heart disease,
and immunodeficiency automatically were associated with 4
points, thus fulfilling the criteria for palivizumab prophylaxis
[5]. The introduction of this RSV risk score tool led to homo-
geneous reimbursement by all Austrian insurance companies
in this population.
Aim of the study was to evaluate the efficacy of this RSV




Retrospectively, all preterm infants of 29 (+0) to 32 (+6)
weeks of gestational age born between January 1, 2004 and
December 31, 2012 at the Department of Pediatrics of the
Medical University Graz, a tertiary care center in the southern
part of Austria, were included for analysis. The study was
approved by the ethic committee of the Medical University
of Graz (number 27-006 ex 14/15) and started in April 2014.
Children were all followed over 2 years including at least
two consecutive RSV seasons from November to April ac-
cording to long-term epidemiological data from Austria [12].
Thus, for every single child included in the study, follow-up
over two RSV seasons was provided. Patients were excluded
for analysis if they were lost to follow-up during the first
2 years of life, or if death occurred during neonatal hospitali-
zation or follow-up. Possible death due to RSV infection was
included in the analysis.
Data collection
Data were collected from the local electronic database
openMedocs with regard to gender, date of birth, gestational
age, birth weight, small for gestational age (defined as birth
weight below the 10th percentile), month of discharge, diag-
nosis of BPD (defined as oxygen dependency at 36 weeks
postmenstrual age), neurological disease (intra-/
periventricular hemorrhage, periventricular leukomalacia),
presence and number of siblings, multiple birth, tobacco
smoking during pregnancy, crowding (more than three per-
sons living under poor conditions), and prescription of
palivizumab prophylaxis as documented in the medical charts
according to the Austrian recommendations for RSV immune
prophylaxis in preterm infants with and without BPD [5].
RSV risk score
With regarding to our study population, recommendations for
palivizumab did not change throughout the study period. The
RSV risk score for preterm infants of 29 to 32 weeks of ges-
tational age is depicted in Table 1 [5]. A score of 4 or more
points qualified an infant for palivizumab prophylaxis. The
risk score was based on literature findings and experts’ rounds
as described in the introduction section. The risk for preterm
infants of 29 to 32 weeks gestational age to exhibit a hospi-
talization due to RSV disease was deemed to be at least twice
as high as the risk for a term and healthy young infant (there-
fore 2 points). For children with severe underlying diseases,
the risk was calculated to be 4 times higher (BPD, CHD, etc.,
all 4 points). Major risk factors were suggested to increase the
risk by 1 time (1 point for neurological disease, birth
weight < 1500 grams, discharge between October 1 and
March 31, or siblings of preschool and school age).
Crowding and low socioeconomic status were defined accord-
ing to Simoes [13]. Otherwise important factors that were
somehow difficult to find out during the parents interview
when evaluating the risk score tool (low socioeconomic sta-
tus/crowding, and passive tobacco smoke exposure) therefore
received only 0.5 points as did the factors of day care atten-
dance (well known, but in Austria only marginally present—
1.3% in the Austrian RSV 29-32 study [2]) and multiple birth
with few studies on its evidence [14]). It was calculated that
nearly all infants of 29 to 32 weeks of gestational age
discharged during the RSV season would have received
palivizumab. In total, it was suggested that not more than
50% of the cohort would be eligible for palivizumab, giving
reassurance that the insurance companies would accept remu-
neration of this model. Acceptance by the insurance compa-
nies was at least the main incitement for the development of
the risk score tool.
RSV hospitalization
RSV hospitalization was defined as hospitalization associated
with LRTI and a positive RSV test result. RSV testing was
performed from nasopharyngeal aspirates using RSV-ELISA
(Directigen EZ RSVTest, Becton Dickinson, USA; sensitivity
66.7–87.2%; specificity 85.5–91.6%). Criteria for hospitaliza-
tion in case of LRTI in general included young age (less than
6 months), signs and symptoms of respiratory distress, history
of prematurity or underlying disease, and/or feeding difficul-
ties. The calculated RSV hospitalization rate included infants
with diagnosis of bronchiolitis (LRI score ≥ 3) not tested for
RSV during the typical RSV season, of whom 70% were
assumed to be RSV-positive. This rate was based on the evi-
dence from the literature that RSVaccounts for 50 to 80% of
all hospitalizations for bronchiolitis during seasonal epidemics
[15,] and according to its use in comparable studies [16].
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Data were collected regarding days of hospitalization due to
respiratory illness, age at admission in months, month of RSV
hospitalization,daysofoxygenrequirement,daysat the intensive
care unit (ICU), days of respiratory support (either nasal contin-
uous positive airway pressure, or mechanical ventilation). In
cases of palivizumab prophylaxis, we did not evaluate the num-
ber of doses of each recipient for further analysis. Severity of
LRTI was measured using the modified lower respiratory
illness/infection (LRI) score ranging from 1 to 5 [17]. In detail:
1 = upper respiratory tract infection, 2 =mild LRTI without re-
spiratory distress (tachypnea, retractions), 3 = moderate LRTI
with respiratory distress without oxygen demand, 4 = severe
LRTI with oxygen demand, and 5 = assisted ventilation.
Statistical analysis
Statistical analysis was performed using Excel (Microsoft
Office, Excel 2013) and SPSS (IBM SPSS Statistics 22). For
categorical data, chi-square test or Fisher’s exact test, and for
numerical data t-test or Mann–Whitney U test were used as
appropriate. Normality assumption was checked using the
Shapiro–Wilk test. Odds ratio and 90% confidence intervals
were calculated using the software package CIA (Confidence
Interval Analysis; version 2.0.0: Statistics with confidence;
London: BMJ Publishing Group, 2000). Statistical signifi-
cance was set at p < 0.05.
Results
Study group
During the study period, 816 preterm infants of 29 to 32weeks
of GA were born. Twenty infants died, seven were lost to
follow-up,and thusthestudypopulationcomprised789infants.
One-hundred and sixty-nine infants (21.4%) were hospitalized
due to respiratory illness during the first 2 years of life for a total
of263 times.Thirty-eight infantswere testedRSV-positive (see
Fig. 1), representing a total RSV hospitalization rate of 4.8%.
Rehospitalizations
Palivizumab prophylaxis was given to 262 infants (33%), of
whom 70 (26.7%) were hospitalized (107 times) due to respira-
tory illness. Of 527 infants without palivizumab prophylaxis, 99
(18.8%) were hospitalized (156 times) due to respiratory illness
(p = 0.005). Nine of 107 rehospitalizations (8.4%) in the
palivizumab group, compared to 32 of 156 rehospitalizations
(20.5%) in the group without prophylaxis, were tested RSV-
positive (p = 0.004; OR 0.356 [CI 90% 0.184–0.689]).
Effect of palivizumab prophylaxis
In the palivizumab group, seven infants (2.7%) were hospital-
ized due to proven RSV infection during the first RSV season,
two outside the first RSV season, and zero during the second
RSV season. In the group without prophylaxis, 25 infants
(4.7%) were hospitalized due to proven RSV infection during
the first RSV season (one infant exhibited two RSV infec-
tions), six outside the first RSV season, and zero during the
second RSV season. Two infants in the palivizumab group
and seven in the group without prophylaxis had no RSV test
done (5.3%); thus, one and five cases respectively were cal-
culated to be RSV-positive. Proven and calculated RSV hos-
pitalization rate during the first RSV season was 3.1% (8/262)
in the palivizumab group and 5.9% (31/527) in the group
without (p = 0.042; OR 0.504 [CI 90% 0.259–0.981]). This
is a 48% relative risk reduction.
Table 1 RSV risk score for
immunoprophylaxis with
palivizumab in preterm infants of
29 to 32 weeks of gestational age
and chronological age below
6 months [5]
Risk factor Score
Gestational age 29–32 weeks and chronological age below 6 months before onset of RSV season 2
Neurological disease* 1
Birth weight < 1500 grams 1
Discharge between October 1 and March 31 1
Siblings of preschool and school age 1
Multiple birth 0.5
Day care attendance 0.5
Low socioeconomic status/crowding 0.5
Passive tobacco smoke exposure 0.5
Bronchopulmonary dysplasia 4
Immune deficiency syndrome 4
Congenital heart disease** 4
4 points and more qualify for palivizumab prophylaxis through the first RSV season
* Including intra-/periventricular hemorrhage, periventricular leukomalacia, hydrocephalus, cerebral infarction
** According to the cardiologist’s recommendation of being hemodynamically significant
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Seasonal distribution
Forty-one hospitalizations due to proven RSV infection oc-
curred in 38 infants during the study period. RSV hospitaliza-
tions peaked in January (nine; 22%) followed by March (sev-
en; 24%), and February and December (each six; 15%). Ten
percent of RSV hospitalizations (n = 4) occurred before onset
of the first RSV season, 80% (n = 43) during the first, and 10%
(n = 4) between first and second season, none during the sec-
ond season.
Risk factors
Palivizumab led to a significant reduction of proven RSV
LRTI in boys (p= 0.037), multiples ((p = 0.026) and infants
discharged during the RSV season(p = 0.044). The risk of
RSV hospitalization increased with the number of risk factors:
presence of one risk factor was associated with a 1.4% RSV
hospitalization rate, two risk factors with a 2.6% rate, three
with a 9% rate, and four with an 8.7% rate in the group with-
out prophylaxis and 0%, 4.6%, 6.1%, and 1.9%, respectively,
in the palivizumab group.
Hospitalization data
There were no differences with regard to length of stay, de-
mand of oxygen, need of mechanical ventilation, admission
rate to the ICU, and severity of infection measured by LRI
scores between groups; details are provided in Table 2.
Discussion
Our study demonstrated efficacy of palivizumab prophylaxis
in a population of preterm infants of 29 to 32 weeks’ gesta-
tional age using a RSV risk score tool developed for Austria
[5]. It was the first evaluation of this risk score tool. The
severity of RSV disease mainly measured by hospitalization
data was not influenced by palivizumab prophylaxis.
Additionally, increasing number of risk factors (up to three
risk factors) increased the risk for RSV hospitalization irre-
spective of palivizumab prophylaxis.
The Impact study group reported on a RSV hospitalization
rate in the palivizumab group of 4.8% [18]. This was the rate
we observed in the non-prophylaxed infants. Thus, our further
reduction of the rate of proven RSV hospitalizations by 2% is
still remarkable. In a real-world perspective, Homaira et al
[19] reported on reduction rates of RSV hospitalizations rang-
ing from 1.2% to 12.4%. Follow-up of 13,310 infants from the
Canadian CARESS study [20] revealed a RSV rehospitaliza-
tion rate of 1.47%. Romero et al. [21] reported on rates lying
between 1.5% and 2.9% over a four-season follow-up from
the US. Pedraz et al. [22] found a rate of 3.95% in Spain, and
















Fig. 1 Flowchart of screened and included preterm infants of 29 to
32 weeks of gestational age born 2004 to 2012, and documentation of
hospitalizations due to respiratory illness within first 2 years of life
Table 2 Data on RSV
hospitalization comparing seven
infants (29 to 32 weeks of
gestational age) with and 26
without palivizumab prophylaxis
during the first RSV season
(November till April)





Length of stay (days) 8 (4–15) 8 (1–21) 0.62
Days on supplemental oxygen 0 (0–12) 0 (0–16) 0.50
Infants with supplemental oxygen 1 (14) 9 (35) 0.30
Mechanical ventilation (days) 0 (0–10) 0 (0–16) 0.91
Infants with mechanical ventilation 1 (14) 5 (19) 0.76
Stay at the ICU (days) 0 (0–15) 0 (0–21) 0.81
Admission to the ICU 2 (29) 6 (23) 0.76
Chronological age (months) 2 (1–6) 4 (1–11) 0.23
LRI score 3 (2–5) 3 (1–5) 0.95
Data are given as median (range) or n (%)
ICU = intensive care unit; LRI score = lower respiratory tract infection score (1–5)
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collected from a palivizumab registry [23]. Preterm infants
born 29 to 32 weeks of GA without BPD who received
palivizumab prophylaxis had a low 1.8% incidence of RSV-
related hospitalizations in a European multicenter study en-
rolling infants younger than 6 months of chronological age
over the 2000/2001 RSV season [24]— a finding comparable
to that observed in the pivotal trial conducted in North
America and the UK [18]. The RSV rehospitalization rate in
our non-prophylaxed group was astonishingly low compared
to other studies reporting on rates ranging from 5.0% to 13.3%
[18, 20, 25, 26].
Increasing numbers of risk factors increased the rates of
RSV hospitalizations in our study, as confirmed by others
[25, 27]. This finding affirms the effectiveness of several risk
score tools in different populations [28–32]. A recent meta-
analysis [33] found eight among 18 risk factors being signif-
icantly associated with RSV associated acute LRTI including
prematurity (odds ratio 1.96), low birth weight (1.91), male
gender (1.23), siblings (1.60), maternal smoking (1.36), a his-
tory of atopy (1.47), no breastfeeding (2.24), and crowding
(1.94). Illness severity was not predicted accurately in a cohort
of term infants [34]. In contrast to other reports [19], we were
unable to document an influence of palivizumab on length of
stay, demand of oxygen, need of mechanical ventilation, ad-
mission rate to the ICU, or severity of infection measured by
LRI scores between groups.
Limitations of the study include the retrospective study
design and the single-center analysis enrolling infants over a
large period of time. On the other hand, the single-center ex-
perience presented here includes homogeneous follow-up data
due to the geographical catchment area. The strength of this
single-center study is the high rate of RSV testing, demon-
strated by the small number of cases that had to be included in
the calculated RSV hospitalization rate. Even in prospective
studies, not all infants were tested for RSV [16]. The model
used in our study for the calculated RSV hospitalization rate is
well established in the literature [16].
Interestingly, the second season revealed no case of RSV
hospitalization, supporting the recommendations for
palivizumab prophylaxis in this population focusing on in-
fants younger than 6 months of chronological age. In total
contrast to existing guidelines on palivizumab prophylaxis
recently, the AAP reported that available data for infants born
at 29 weeks, 0 days gestation, or later did not identify a clear
gestational age cutoff for which the benefits of prophylaxis
might be clear, and for this reason, infants born at 29 weeks,
0 days gestation, or later are not universally recommended to
receive palivizumab prophylaxis [35]. This is an astonishing
revision of the former recommendations by the AAP that is
not based on epidemiologic data and the proven burden of
RSV disease in this particular gestational age group [1].
Approximately one quarter of RSV hospitalizations oc-
curred outside the typical RSV season and, hence, will not
be influenced by palivizumab prophylaxis. This is a well-
known phenomenon, as is the year-to-year variability of
RSV activity [12, 25]. Thus, epidemiological studies are re-
quested to cover at least two or more RSV seasons.
In conclusion, the Austrian risk score tool— developed for
palivizumab prophylaxis in infants of 29 to 32 weeks of GA
— led to a reduction of RSVassociated hospitalizations in our
single-center retrospective analysis without influencing the
severity of RSV disease.
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